Shots:

• The P-IIb (NEST-IN1) study is to find the safety, efficacy & immunogenicity of HIL-214 (n=1,425) vs PBO (n=1,399) among infants (age: 5mos.) during initial vaccination across the US & LATAM, with 51 1EPs
• Study did not reach its 1EP & 2EP demonstrating effectiveness of 5% against moderate or severe AGE events caused by GI.1 or GII.4 norovirus genotypes; safety & immunogenicity aligned with the prespecified analysis in the first 200 individuals across NEST-IN1 & prior studies
• The company plans to halt the NEST-IN1 trial in infants, conducted due to favorable results in P-IIb (NOR-211) among adults, and advance HIL-214 & P-I-ready HIL-216 vaccine for adult population

Ref: HilleVax | Image: HilleVax

Related News:- Vertex Receives CHMP’s Positive Opinion for Kalydeco as a Treatment of Cystic Fibrosis in Infants

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com